Table 4.
Animal studies in which soy components, soymilk, fermented soymilk or Cuminum cyminum were used as dietary supplements for diabetes management in animal models
| Author | Animal model | Compound | Amount and duration | Fasting blood glucose* | TG* | TC* | LDL-C* | HDL-C* | Body weight* | Reference |
|---|---|---|---|---|---|---|---|---|---|---|
| Lu et al. | Diabetic-STZ rats | high-isoflavone soy protein | 20%/For 8 weeks | Significantly decreased | ND | ND | ND | Significantly increased | Significantly increased | 21 |
| Lee et al. | Diabetic-STZ rats | genistein supplement | 600 mg/kg diet/For 3 weeks | Significantly decreased - 19.6** | Significantly decreased | Significantly decreased | ND | Significantly increased | ND | 19 |
| isolated soy protein supplement | 200 g/kg /For 3 weeks | Significantly decreased -24.9 | Significantly decreased | Significantly decreased | ND | Significantly increased | ND | |||
| Marazza et al. | Diabetic-STZ mice | soymilk | 5 ml/day/For 28 day | Significantly decreased | Significantly decreased | Significantly decreased | Significantly decreased | No effect | Significantly increased | 10 |
| soymilk fermented with Lactobacillus rhamnosus CRL981 | 5 ml/day/For 28 day | Significantly decreased - 40.2 | Significantly decreased | Significantly decreased | Significantly decreased -20 | No effect | Significantly increased | |||
| Mohammadi Sartang et al. | Diabetic-STZ rats | Soymilk | 1 mL/day/For 28 days | Significantly decreased - 35.8 | Significantly decreased | Significantly decreased | No effect | Significantly increased 20.4 | Significantly increased + 18.54 | 30 |
| fermented soymilk (by Bifidobacterium lactis) | 1 mL/day/For 28 days | Significantly decreased - 39.3 | Significantly decreased | Significantly decreased | No effect | Significantly increased 24.8 | Significantly increased + 19.02 | |||
| fermented soymilk fortified with omega-3 | 1 mL/day/For 28 days | Significantly decreased -47.2 | Significantly decreased -39.30 | Significantly decreased -20.80 | No effect | Significantly increased 14.8 | Significantly increased + 21.48 | |||
| Willatgamuwa et al. | Diabetic-STZ rats | Cumin powder | 1.25% of diet/For 8 weeks | Significantly decreased - 50 | ND | ND | ND | ND | A slight increasing | 40 |
| Jagtap et al. | Diabetic-STZ rats | Metthanolic extract of seeds of C.cyminum | 200 mg/day/For 28 days | Significantly decreased | ND | ND | ND | ND | Significantly increased | 14 |
| Metthanolic extract of seeds of C.cyminum | 400 mg/day/For 28 days | Significantly decreased | ND | ND | ND | ND | Significantly increased | |||
| Metthanolic extract of seeds of C.cyminum | 600 mg/day/For 28 days | Significantly decreased | ND | ND | ND | ND | Significantly increased | |||
| Srivsatava et al. | High fructose fed diabetic- STZ rats. | Ethanolic extract of seeds of C. cyminum | 250 mg/Kg body weight/For 14 days | Significantly decreased | Significantly decreased -21.04 | Significantly decreased - 22.7 | Significantly decreased - 16.9 | Significantly increased + 12.2 | ND | 37 |
| Present study | Diabetic STZ-NA rats | SM | 1 ml/day/For one month | Significantly decreased -44.45 | -34.56 | -7.85 | -25.8 | +18.56 | Significantly increased + 10.99 | - |
| PSM | 1 ml/day/For one month | Significantly decreased -71.92 | -46.37 | -23.42 | Significantly decreased - 64.79 | Significantly increased + 34.87 | Significantly increased + 26.94 | |||
| SMC | 1 ml/day/For one month | Significantly decreased -53.14 | -40.5 | -23.47 | Significantly decreased - 58.96 | +23.48 | Significantly increased + 18.76 | |||
| PSMC | 1 ml/day/For one month | Significantly decreased -73.69 | Significantly decreased - 71.27 | Significantly decreased - 32.17 | Significantly decreased - 60.24 | Significantly increased + 46.05 | Significantly increased + 28.18 |
C=Control; SM=Soy milk; PSM=Probiotic soy milk; SMC=Soy milk containing essential oil of C. cyminum; PSMC=Probiotic soy milk containing essential oil of C. cyminum; ND=Not determined; *Comparison with the diabetic control group; **Percent change compared to the diabetic control group.